2006 Scientific Sessions at PHA International PH Conference

Abstracts

• Effect of Prostacyclins on Thrombocytopenia in Portopulmonary Hypertension
  Golbin JM, Krowka MJ
• Right Heart Catheterization is Necessary to Confirm and Further Characterize Portopulmonary Hypertension
  Krowka MJ, Swanson KL, Frantz RP, McGoon MD
• The Plasma Proteome in Pediatric Idiopathic Pulmonary Arterial Hypertension: A Compelling Case for Angiogenesis in Patients who Respond to Vasodilator Therapy
  Davie NJ, Fox S, Clausen L, et al.
• Endothelin-1 Up-regulates Plasminogen Activators and Plasminogen Activator Inhibitor- type1 Gene Expression in Cultured Human Pulmonary Endothelial Cells
  Tabengwa E, Barchue J, Benza RL, Pan W
• Human Analogue BNP in the Management of Right Heart Failure due to Secondary Pulmonary Hypertension
  Jameel MN, Colvin-Adams MM
• Ultrafiltration: A Safe and Effective Treatment for Right Ventricular Failure due to Pulmonary Hypertension
  Taylor A, Colvin-Adams MM, Miller LW, Jameel MN, Boyle AJ, Missov E
• Successful Liver Transplantation Following Medical Management of Portopulmonary Hypertension; a Single Center Series
  Frost AE, Sussman NL, Vierling JM, et al.
• B-type natriuretic peptide (BNP) response to six-minute walk test (6MWT) in Pulmonary Arterial Hypertension (PAH)
  Safdar Z, Frost AE
• Pulmonary vascular adaptations in swine with secondary pulmonary hypertension after myocardial infarction- role of endothelin
  Houweling B, Merkus D, Boomsma F, Duncker DJ
• rhVEGF Treatment Preserves Pulmonary Vascular Reactivity and Structure in an Experimental Model of Pulmonary Hypertension in Fetal Sheep
  Grover TR, Parker TA, Markham NE, Abman SH
• Cognitive Impairment is Common in Patients with Pulmonary Arterial Hypertension
  Hansen-Flaschen J, Palevsky H, Taichman D, et al.
• Simvastatin Potently Suppresses Rho-Kinase in Chronic Hypoxic Pulmonary Hypertension
  Girgis RE, Shimoda L, Tuder RM, et al.
• Elevated plasma endothelin-1 (ET1) levels are associated with death in newborns with congenital diaphragmatic hernia (CDH)
  Keller RL, Hawgood S, Fineman JR, Tacy TA, Xu J, Hendricks-Munoz K
• A Novel Gas Exchange Assist Device in Juvenile Porcine Acute Lung Injury
  El-Ferzli GT, Ambalavanan N, Bulger A, III PJB
• Role of integrins in hypoxic pulmonary hypertension: expression and mobilization of intracellular Ca2+ in rat pulmonary arterial smooth muscle cells (PASMCs)
  Umesh A, Sham JSK, Thompson MA, Yip KP, Chini EN
• Thrombospondin-1 in Hypoxic Pulmonary Vascular Remodeling
  Ochoa CD, Hales CA, Quinn DA, Hasak SL, Al-Ansari E, Yu L
• The bone morphogenetic protein type II receptor regulates bone morphogenetic protein signaling and function in pulmonary vascular smooth muscle cells
  Yu PB, Ichinose F, Bloch KD, Deng DY, Beppu HB, Kawai NK
• Single Center Experience with Rapid Dose Escalation of Sub-Cutaneous (SQ) Treprostinil for the Treatment of Pulmonary Arterial Hypertension
  Soto FJ, Derksen T, Janusz J, Presberg K
• Changes in V Wave During a Nitric Oxide Vasodilator Trial for Pulmonary Hypertension: Unmasking Left Heart Disease
  Marks D, Soto FJ, Kleczka J, et al.
• Estimation of Cardiac Index in Patients with Pulmonary Hypertension: Thermal Dilution vs. Fick's Method
  Marks D, Soto FJ, Kleczka J, Siegel R, Presberg K
• PRX-08066: A Potent 5-HT2B Receptor Antagonist with a dual disease modifying/vasodilating mechanism for the Treatment of Pulmonary Hypertension
  Rutkowski J, Guérin GA, Noiman S, et al.
• Relationship of BMRP2 Mutations and Vasoreactivity in Pulmonary Arterial Hypertension
  Elliott CG, Ward K, Schmidt JW, et al.
• Ambulatory right ventricular and pulmonary artery pressure response to treatment with bosentan and treprostinil in patients with pulmonary arterial hypertension
  Bourge R, McGoon M, Barst RJ, et al.
• Relation Between Pulmonary Arterial Pressure Response and Exercise Tolerance in Pulmonary Arterial Hypertension Patients Treated with Bosentan or Treprostinil
  Frantz RP, Bennett T, Roettger A, et al.
• Hemodynamic response during six-minute walk tests and during daily living in patients with pulmonary arterial hypertension
  Bourge R, Benza RL, Kjellstrom B, et al.
• Comparison of Sitaxentan and Bosentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases
  Highland KB, Strange C, Girgis R, Black C
• Right Index of Myocardial Performance (RIMP) as a Predictor of Death or Lung/Heart Transplantation in Patients with Pulmonary Hypertension (PH)
  Abhayaratna WP, Wiste JA, Barnes ME, et al.
• Left Atrial Volume as an Indicator of Left Heart Disease in Patients with Pulmonary Hypertension
  Wiste JA, Barnes ME, Murphy JG, et al.
• Acute Vasoreactivity and Genetic Polymorphisms in IPAH/FPAH Children and Adults
  Rosenzweig EB, Knowles J, Barst RJ, Morse J, Khan M, Diamond B
• Pulmonary Hypertension in Children with Sickle Cell Disease
  Sheth SS, Khan MA, Small T, et al.
• Combination Therapy with Sildenafil and Bosentan and Epoprostenol Weaning in Patients with Pulmonary Arterial Hypertension
  Frantz RP, DeZiel TA, Koenig LJ, McGoon MD
• The effects of eNOS deficiency on pulmonary vascular remodeling in pulmonary hypertension
  Chesler N, Vanderpool R, Tuchscherer H, Kersten E, Kobs R
• Quercetin Represses NADPH oxidase subunit p22phox Gene Expression: A Molecular Mechanism to Control ROS-Linked Functions and Dysfunction
  Wolkowicz PE, Grenett HE, Olave NC, Pasten MC, Benza RL
• One Year Experience with Intravenous Treprostinil in Pulmonary Arterial Hypertension (PAH) Patients
  Benza RL, Krichman A, McLaughlin VV, et al.
• Efficacy of Sildenafil Treatment and Improved Survival After 1 Year in Patients With Pulmonary Arterial Hypertension (PAH)
  McLaughlin V, Chong C, Collings L, Rubin LJ
• Registry to EValuate Early And Long-term PAH Disease Management (REVEAL Registry™)
  Pennington J, Feldkircher K, Krichman A, et al.
• Etiology specific reductions in pulmonary endothelial angiotensin converting enzyme activity in patients with PAH and Chronic Thromboembolic PH
  Langleben D, Catravas J, Orfanos S, Giovinazzo M, Hirsch A
• Brain Natriuretic Peptide Levels in Patients With PAH Attending the 2004 Miami PHA Meeting: Relationship to Diuretic Requirement and WHO Class
  McGoon MD, Frantz RP, Severson CJA, Durst LA, Tointon SK
• Severe Chronic Pulmonary Hypertention Sheep Model by Continuous Intravenous Air Infusion Induced Pulmonary Air Embolism
  Zwischenberger JB, Zhou X, Wang D, Castro C, Hawkins H
• Correction of rheological properties of blood in severe chronic obstructive pulmonary disease patients with pulmonary hypertension
  Gavrisyuk VK, Gumenyuk NI, Yachnik AI, Dzyublik YA
• Rapid switch from Intravenous Epoprostenol to Intravenous Treprostinil in patients with pulmonary arterial hypertension
  Sitbon O, Humbert M, Galie N, et al.
• Long-term follow-up and survival of BMPR2 mutation positive vs. negative patients
  Schmidt JW, Leppert, Ward K, et al.
• BMPR2 Mutations Are Not Found In Portopulmonary Hypertension Patients
  Kim M, Glissmeyer E, Elliott CG, Carlquist J, Schmidt J
• Basic Science A Single-Nucleotide Polymorphism (-254 C to G) in the TRPC6 Gene is Associated with Idiopathic Pulmonary Arterial Hypertension
  Yuan JX-J, Rubin LJ, Yu Y, Vangala N, Landsberg JW, Nicholson A
• Diagnostic Criteria for Clinical Science Idiopathic Pulmonary Arterial Hypertension (IPAH) Do Not Reflect Patients Treated for IPAH at a Referral Pulmonary Hypertension (PH) Clinic
  Edwards B, McCully R, Swanson K, et al.
• "Unexplained” Pulmonary Hypertension and Normal Ejection Fraction in Elderly Patients: Idiopathic Pulmonary Arterial Hypertension or Diastolic Heart Failure?
  Shapiro BP, Redfield MM
• Calcium Channel Blockers Impair Right Atrial Contractility and Cardiac Output in Non-Responders with Chronic Pulmonary Hypertension
  Zierer A, Patterson GA, Moon MR, Gaynor SL, Maniar HS, Steendijk P
• Short-Term Mortality in Patients After Single or Bilateral Lung Transplantation for Idiopathic Pulmonary Arterial Hypertension: Analysis of the UNOS Database
  Daud SA, Hachem RR, Yusen RD, Chakinala MM
• Preparatory clinical study on treatment of pulmonary arterial hypertension associated with connective tissue diseases with sildenafil: experience from a Chinese academic hospital
  Fengchun Z, Yan Z, Mengtao L, Xiaofeng Z, Qian W, Zhuang T
• Dramatic Pulmonary Vascular Changes in a Liver Transplant Candidate
  Golbin J, Krowka MJ
• Ambrisentan Improves Exercise Capacity and Time to Clinical Worsening in Patients with Pulmonary Arterial Hypertension: Results of the ARIES-2 Study
  Oudiz RJ, Rubin LJ, McGoon MD, et al.
• Do Liver Function Abnormalities With Bosentan Recur With Sitaxsentan?
  Coyne TC, Alford KL, Henry NS, Dixon R
• No Clinical Interaction between Sitaxsentan and Sildenafil
  Coyne TC, Kramer W
• Sildenafil Improves Exercise Ability and Hemodynamics in Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
  Hill N, Burgess G, Badesch DB
• Long-Term Safety Profile of Bosentan in Patients With Systemic Sclerosis and Pulmonary Arterial Hypertension: Results From the TRAX Database
  Humbert M, Segal E, Carlsen J, et al.
• Combination of Bosentan with Prostanoids or Sildenafil in Pulmonary Arterial Hypertension was Well Tolerated: Results from the TRAX Database
  Humbert M, Carlsen J, Kiely DG, Hoeper MM, Segal E
• Long-Term Benefits of Sildenafil Treatment on Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension
  Doughty N, Collings L, Gilbert C, Pepke-Zaba J
• Hemodynamic Comparisons Between Transthoracic Doppler Echocardiography and Right Heart Catheterization in Patients with Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis
  Swanson KL, Utz JP, Krowka MJ
• BREATHE-5: Bosentan improves hemodynamics and exercise capacity in the first randomized placebo-controlled trial in Eisenmenger physiology
  Berger R, Landzberg M, Lauer A, et al.
• Clinical Science Delivery of Intravenous Treprostinil at Low Infusion Rates Using a Miniaturized Infusion Pump in Patients with Pulmonary Arterial Hypertension
  Barst RJ, Zaccardelli D, Laliberte K, et al.